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Drs. Hoeper and Welte are correct in their suggestion that there is a linear trend in the response among the doses in the hemodynamic measures and in the percentages of patients who improved by at least one WHO functional class. The absence of a dose-response effect on the primary end point (exercise capacity) or on tolerability with the three sildenafil doses (20 mg, 40 mg, and 80 mg three times daily) may be related to complete inhibition of phosphodiesterase type 5 with the lowest dose. However, in the extension study, all patients were treated with 80 mg three times daily (if tolerated), and we do not have prospective information on the long-term efficacy of the approved dose of 20 mg three times daily. Based on these data, 20 mg three times daily appears to be a reasonable initial dose; an increase to 40 mg three times daily, 80 mg three times daily, or both may be considered in order to achieve or maintain favorable effects. We recognize that limited data are currently available regarding the optimal dose of sildenafil for long-term treatment and that the use of higher doses may be hampered by the restricted approval. Nazzareno Galiè, M.D. 
1.

2.
Congenital Glutamine Deficiency with Glutamine Synthetase Mutations
To the Editor: Häberle et al. (Nov. 3 issue) 1 state that "the concentration of glutamate . . . was not elevated in either of the two patients, but this lack of elevation might be due to the various other pathways of glutamate catabolism." We suggest that low-to-deficient glutamate concentrations in cerebrospinal fluid indicate a chronic depletion of neuronal glutamate stores, since astrocytic glutamine synthase is crucial for their replenishment. After the bioenergetic coupling of and metabolite trafficking between astrocytes and neurons occur, 2 a complete deficiency of this enzyme should result in a severe depletion of neuronal glutamate stores in the long run and, subsequently, a drain of intermediates of the tricarboxylic acid cycle due to increased new synthesis of glutamate and insufficient anaplerosis through pyruvate carboxylation in neurons. 3 As a consequence, concentrations of glutamate in the cerebrospinal fluid may decrease, as seen in both patients mentioned above. Neurotransmission of glutamate is important for the developing brain, for modulating neuronal migration, for growth spurts of the brain, and for apoptosis. 4 Dysfunction of these mechanisms probably induces brain damage and malformations, 5,6 as displayed in both patients. 
To the Editor:
We read with interest the report by Häberle et al., which indicates that systemic glutamine deficiency due to a glutamine synthetase gene mutation results in brain malformations and seizures. An additional explanation might be related to chronic hyperammonemia resulting from a deficiency of glutamine synthetase. However, levels of ammonia were not reported. Glutamine synthetase not only produces glutamine but also detoxifies ammonia. 1 In the brain, glutamine synthetase fuels glutamate uptake by astrocytes; therefore, inhibition of glutamine synthetase results in increased extracellular glutamate levels and excitotoxic effects, leading to seizures. 2 Hyperammonemia in the setting of liver failure leads to neurologic impairment. Also, infants with enzyme abnormalities of the urea cycle, such as a deficiency of ornithine carbamoyltransferase, who survive episodes of hyperammonemia have a high incidence of mental retardation and cerebral palsy. 3 In patients with lung transplants, hyperammonemia resulting from hepatic glutamine synthetase deficiency is associated with high mortality. 4 The observation of increased glutamine synthetase protein levels in the presence of reduced activity supports the view that hyperammonemia may set up a self-perpetuating cycle whereby ammonia can reduce glutamine synthetase activity. 5 Therefore, it is possible that the inhibition of glutamine synthetase in the brain may lead to increased levels of ammonia and extracellular glutamate in the brain, partly explaining the clinical observations. Christopher Rose, Ph.D.
